Literature DB >> 18281552

Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.

Danielle Boller1, Alexander Schramm, Kathrin T Doepfner, Tarek Shalaby, André O von Bueren, Angelika Eggert, Michael A Grotzer, Alexandre Arcaro.   

Abstract

PURPOSE: The phosphoinositide 3-kinase (PI3K)/Akt pathway is frequently activated in human cancer and plays a crucial role in neuroblastoma biology. We were interested in gaining further insight into the potential of targeting PI3K/Akt signaling as a novel antiproliferative approach in neuroblastoma. EXPERIMENTAL
DESIGN: The expression pattern and functions of class I(A) PI3K isoforms were investigated in tumor samples and cell lines. Effects on cell survival and downstream signaling were analyzed following down-regulation of p110alpha or p110delta in SH-SY5Y and LA-N-1 cells by means of RNA interference.
RESULTS: Overexpression of the catalytic p110delta and regulatory p85alpha isoforms was detected in a panel of primary neuroblastoma samples and cell lines, compared with normal adrenal gland tissue. Although down-regulation of either p110alpha or p110delta led to impaired cell growth, reduced expression of p110delta also had a selective effect on the survival of SH-SY5Y cells. Decreased levels of p110delta were found to induce apoptosis and lead to lower expression levels of antiapoptotic Bcl-2 family proteins. SH-SY5Y cells with decreased p110delta levels also displayed reduced activation of ribosomal protein S6 kinase in response to stimulation with epidermal growth factor and insulin-like growth factor-I.
CONCLUSIONS: Together, our data reveal a novel function of p110delta in neuroblastoma growth and survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281552     DOI: 10.1158/1078-0432.CCR-07-0737

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.

Authors:  Susanne Fransson; Katarina Ejeskär
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

3.  PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.

Authors:  Feifei Wen; Shuang He; Chenbo Sun; Tangyue Li; Shuhua Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 4.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

5.  Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Richard Gorlick; E Anders Kolb; Raushan T Kurmasheva; Stephen T Keir; John M Maris; Catherine A Billups; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

6.  PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

Authors:  Fabienne Schmit; Tamara Utermark; Sen Zhang; Qi Wang; Thanh Von; Thomas M Roberts; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

7.  Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.

Authors:  Anna Wojtalla; Fabiana Salm; Ditte G Christiansen; Tiziana Cremona; Paulina Cwiek; Tarek Shalaby; Nicole Gross; Michael A Grotzer; Alexandre Arcaro
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  Intersectin 1 is required for neuroblastoma tumorigenesis.

Authors:  A Russo; J P O'Bryan
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 9.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

10.  Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.

Authors:  Jane Renshaw; Kathryn R Taylor; Ryan Bishop; Melanie Valenti; Alexis De Haven Brandon; Sharon Gowan; Suzanne A Eccles; Ruth R Ruddle; Louise D Johnson; Florence I Raynaud; Joanna L Selfe; Khin Thway; Torsten Pietsch; Andrew D Pearson; Janet Shipley
Journal:  Clin Cancer Res       Date:  2013-08-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.